 

Active Ingredient: Atazanavir Sulfate; Cobicistat 

 

Dosage Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: EQ 300 mg base/150 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: Females should not be pregnant or lactating, and, if applicable, 
should practice abstention or contraception during the study. 

 

2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: EQ 300 mg base/150 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: See comments above. 

 

Analytes to measure (in appropriate biological fluid): Atazanavir and cobicistat in plasma 

 

Bioequivalence based on (90% CI): Atazanavir and cobicistat 

 

Waiver request of in vivo testing: Not applicable 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 


